| 前收市價 | 46.55 |
| 開市 | 46.55 |
| 買盤 | 49.40 |
| 賣出價 | 50.65 |
| 拍板 | 270.00 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 46.55 - 46.55 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 35 |
ZacksAmgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Motley FoolMeet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug?
